- The rise in obesity is having a massive impact on the global economy, according to Goldman Sachs.
- The bank estimates that obesity will drag down the world’s GDP by $4 trillion in 2035.
- But a new class of weight-loss drugs could change all of that, and represents a big opportunity for investors.
Obesity is prevalent throughout the US, and that’s having a massive impact on the economy, according to Goldman Sachs.
The bank estimates that obesity is costing the US healthcare system $170 billion per year. And by 2035, Goldman Sachs estimates that the consequences of the chronic health condition will drag down global GDP by $4 trillion.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased